NASDAQ$ETNB
89Bio Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
89bio reported its financial results for the fourth quarter and full year ended December 31, 2024, with a net loss of $118.4 million and a diluted EPS of -$1.02.
89bio, a clinical-stage biopharmaceutical company, reported a net loss of $118.4 million for the fourth quarter of 2024, an increase from the $40.2 million net loss in the same period last year. This was primarily driven by higher research and development expenses due to contract manufacturing and the advancement of Phase 3 programs, as well as increased general and administrative expenses.
- Net loss for Q4 2024 was $118.4 million, significantly higher than $40.2 million in Q4 2023.
- Diluted EPS for Q4 2024 was -$1.02, compared to -$0.50 in Q4 2023.
- Research and development expenses increased to $111.3 million in Q4 2024 from $33.6 million in Q4 2023, primarily due to milestone payments and clinical trial costs.
- Cash, cash equivalents, and marketable securities totaled $439.955 million as of December 31, 2024.
Headline financials
Revenue & EPS history
89Bio · Revenue · Quarterly
$0
Forward guidance
89bio anticipates continued progress in its clinical trials for MASH and SHTG, with topline histology data for ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis expected in 1H 2027 and 2028, respectively. Topline data for the ENTRUST trial in SHTG is now expected in 1Q 2026.
Tailwinds
- ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials continue to advance with topline histology data expected in 1H 2027 and 2028.
- Data from histology cohorts of both trials are intended to support accelerated approval in the United States and conditional approval in Europe.
- The company remains on track for potential Biologics License Application (BLA) and Marketing Authorization Application (MAA) filings, pending positive clinical data.
- Pegozafermin has the potential to significantly impact the lives of patients suffering from advanced MASH and SHTG due to its robust fibrosis benefit, tolerability, safety profile, and convenient dosing.
- Completed follow-on equity offerings in 4Q 2024 and 1Q 2025 for gross proceeds of $143.7 million and $287.5 million, respectively, strengthening financial position.
Headwinds
- Topline data for the Phase 3 ENTRUST trial in SHTG is now expected in 1Q 2026, a delay from previous expectations.
- The unblinding of the ENTRUST trial will occur after study completion at Week 52, which may introduce potential bias if data were unblinded earlier.
- The company's ability to obtain accelerated approval and full approval is contingent on positive results from Phase 3 trials.
- Future results from clinical studies may not necessarily be predictive of the results of ongoing clinical studies.
- The company faces risks and uncertainties, including those related to general economic, health, industrial, or political conditions, and competition from other products.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports · overlaid with Q4 2024
-0.1%
Avg return
Earnings day
-4.6%
Avg return
5 days after
-2.8%
Avg return
30 days after
54%
13 / 24 earnings
Positive
+14.8%
Q4 2019
Best reaction
-19.4%
Q1 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | +1.7% | +1.3% | -1.7% | |
| Q1 2025 | -3.7% | -4.1% | +18.6% | |
| Q4 2024 | -1.0% | -7.1% | -3.7% | |
| Q3 2024 | +2.8% | -10.9% | -20.6% | |
| Q2 2024 | -10.9% | -11.8% | -0.9% | |
| Q1 2024 | -3.5% | +0.8% | -10.2% | |
| Q4 2023 | +7.3% | -0.2% | -1.3% | |
| Q3 2023 | -11.8% | — | — | |
| Q2 2023 | +5.3% | — | — | |
| Q1 2023 | +1.3% | — | — | |
| Q4 2022 | -1.1% | — | — | |
| Q3 2022 | +14.2% | — | — | |
| Q2 2022 | +3.6% | — | — | |
| Q1 2022 | +14.6% | — | — | |
| Q4 2021 | +5.1% | — | — | |
| Q3 2021 | +1.4% | — | — | |
| Q2 2021 | +1.1% | — | — | |
| Q1 2021 | -19.4% | — | — | |
| Q4 2020 | -4.7% | — | — | |
| Q3 2020 | -0.8% | — | — | |
| Q2 2020 | +1.6% | — | — | |
| Q1 2020 | -6.2% | — | — | |
| Q4 2019 | +14.8% | — | — | |
| Q3 2019 | -13.5% | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro